Today we announce a new breakthrough in malaria. Novartis has received approval for the first malaria medicine for newborn babies and young infants. The positive decision from Swissmedic under a special global health initiative is now expected to lead to rapid approvals across eight African countries. But we’re not done. Building on our three-decade track record developing malaria medicines, we are going further. Together with our partners, we are harnessing our unique capabilities as an innovative medicines company to develop four new antimalarial compounds with the potential to combat drug resistance. This is part of nearly USD 490 million in funding for global health R&D since 2021, which has helped to create the industry’s No. 1 pipeline of treatments for malaria and neglected diseases. Medicines for Malaria Venture | European & Developing Countries Clinical Trials Partnership (EDCTP)
Amazing!
Thanks to Vas Narasimhan, Shreeram Aradhye, Fiona H. Marshall, Lutz Hegemann for your commitment and support to Global Health and thanks to the amazing team for their perseverance and hard work in bringing this much needed medicine to the smallest of children.
Well done!
Congratulations!
A proud moment for Novartis and global health. This approval marks a critical step forward in protecting the youngest and most vulnerable from the threat of malaria. We’re not stopping here. With our partners, we’re advancing a robust pipeline of breakthrough innovations to stay ahead of drug resistance and drive lasting impact.
It’s a great achievement! Congratulations 🙌
Congrats! 🎉
Congratulations to the Novartis team on this significant milestone for global health. Delivering the first approved malaria treatment for newborns and young infants is a remarkable achievement. Your continued commitment to innovation and collaboration is setting new standards in the fight against malaria and drug resistance.
"Incredible step by Novartis! A much-needed move for protecting infants from malaria.👏
Innovation to impact | On a pursuit to reduce healthcare gaps by advancing access to innovative treatments globally 🌍 ⚖️ ⚕️
3wProud moment. Three decades is not a small feat Novartis